SCHEMBL5111445

SCHEMBL5111445

COc1cccc(F)c1C(=O)Nc1c[nH]nc1-c1nc2c([nH]1)CCNC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
ABL1 P00519 1/20 0.42
SRC P12931 1/20 0.42
AURKA O14965 1/20 0.39
AURKB Q96GD4 1/20 0.39
POLB P06746 2/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C19 P33261 1/20 0.38
ATR Q13535 2/20 0.36
MAP4K1 Q92918 1/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
THRB P10828 1/20 0.35
RECQL P46063 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5105503 0.92 MEN1 (0.38) CCNA2CDK2POLBKMT2AMEN1
SCHEMBL5111561 0.85 RAB9A (0.43) POLBKMT2AMEN1MAPTALDH1A1
SCHEMBL5106436 0.84 ABL1 (0.43) CCNA2CDK2ABL1SRCAURKA
SCHEMBL5105859 0.82 CCNA2 (0.38) CCNA2CDK2ATR
SCHEMBL5110963 0.82 CDK5 (0.39) CCNA2CDK2ABL1SRCAURKA
SCHEMBL5112835 0.81 ATR (0.42) CCNA2CDK2ABL1SRCAURKA
SCHEMBL5102362 0.81 RBP4 (0.39) CCNA2CDK2ABL1SRCAURKA
SCHEMBL5106663 0.81 ABL1 (0.38) CCNA2CDK2ABL1SRCAURKA
SCHEMBL5578091 0.81 ABL1 (0.44) CCNA2CDK2ABL1SRCAURKA
SCHEMBL8305589 0.79 KMT2A (0.56) ABL1SRCAURKAAURKBPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors ASTEX THERAPEUTICS LIMITED (UK) 2008-01-03 US disclosed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP disclosed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004270-A1 3,4-Disubstituted Pyrazoles as Cyclin Dependent Kinases (Cdk) or Aurora Kinase or Glycogen Synthase 3 (Gsk-3) Inhibitors CDK3, CDK1, GSK3B CCNA2 64/4885CDK2 13/4885ABL1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.